Search Results for "Ncs Diagnostics Inc Canada"

17:30 EST 24th November 2014 | BioPortfolio

Original Source: Somagen Diagnostics

Somagen was founded as Immucor Canada Inc. in 1988 by Thomas E Brown and Roland Person. In its early days the business focused on supplying the Canadian Blood Bank market. By 1995 the company had begun expanding into other niche laboratory markets and then acquired NCS Diagnostics in a significant step toward expansion. Kevin Blackburn, who would become the company's third partner, joined the business in 1996. Expansion into new markets within the clinical lab continued over the next several years. Immucor ...

Matching Channels


Roche is the 5th largest pharmaceutical company in the world, based on annual sales, which were recorded at $36,017m in 2009. The pharmaceutical products of Roche are major players in the followin...

Hepatitis B Immune Globulin Cangene

HepaGam B® [Hepatitis B Immune Globulin (Human) Injection] contains purified antibodies specific for the hepatitis B surface antigen (HBsAg). * It is approved in Canada and the United States f...

Alto Marketing - specialist healthcare and life science communications consultancy

Alto Marketing is a committed and forward-thinking specialist healthcare and life science communications consultancy.  With extensive experience of worldwide marketing in sectors including (...


Siemens Healthcare is the second largest medical devices company in the world (based on annual sales), with sales of $17.4 billion. Specializing in the imaging, IT, diagnostics and workflow soluti...


In addition to the world famous Cambridge University, Cambridge and its surrounding area is a hub of globally reaching biotechnology companies. With more than 247 companies, and the high quality res...

Matching News

Miacom diagnostics receives Health Canada approval for hemoFISH assays

Germany-based Miacom diagnostics has received approval from the Health Canada for its hemoFISH assays, which are designed to help identify and differentiate bacterial pathogens from positive blood cul...

Valeant buys NicOx’ US ophthalmic diagnostics unit

Ophthalmology-focused French biotech firm NicOx says that Canada’s Valeant Pharmaceuticals International has acquired NicOx' US diagnostics subsidiary NicOx Inc.

People on the move (week of September 22)

A bi-weekly roundup of People on the move in Canada’s life science and biotech sectors. Proteocyte Diagnostics announces the appointment of Dr. Mario Thomas to the role of president. With over 25 ye...

International Veterinary Diagnostics (Clinical Chemistry, Hematology Analyzers, Molecular Diagnostics, Immunodiagnostics, Diagnostics Imaging) Market - Forecasts to 2018

Dublin, July 1, 2014 (GLOBE NEWSWIRE) -- Research and Markets (  has announced the addition of the "International Veterinary Diagnostics ...

AstraZeneca Partners with Roche on Development of a Companion Diagnostic

The topic of companion diagnostics has been of continuing interest for me. I have posted a number of notes about this type of lab test (see, for example: More Details About Roche's Companion Diagnosti...

WOUNDCHEK™ Laboratories receives market clearance for WOUNDCHEK™ Protease Status in Canada

WOUNDCHEK™ Laboratories announced today that it has received market clearance from Health Canada for WOUNDCHEK™ Protease Status, the world’s first point of care

Leading Commentary on Molecular Diagnostics Edited by LGC Expert

The application of molecular technology in clinical diagnosis is a rapidly developing area and is predicted to greatly improve the speed, efficiency and accuracy of diagnostic medicine. A book looking...

Easy-to-use companion diagnostics draw Abbott, Biocartis into joint development deal

Belgo-Swiss molecular diagnostics developer Biocartis and US healthcare products maker Abbott Laboratories (NYSE:ABT) will jointly develop and market multiplex companion diagnostics tests, combining B...

Matching PubMed Articles

Structured diagnostics and therapy of the CUP syndrome.

In the majority of cases, patients with cancer of unknown primary (CUP) have a poor prognosis with no prospect of being cured. Hence, a reasonable focus of diagnostics on its essential targets seems a...

What Does the Cochrane Collaboration Say about Behavioural Change?

A great oak in the forest of rehabilitation has fallen.

Clinician's Commentary on Kelland et al.(1.).

Clinician's Commentary on Fleet et al.(1.).

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement